This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
National Vision's Store Launches on Track Despite Cost Woes
by Zacks Equity Research
National Vision (EYE) adopts a formula-based approach to open around 75 stores in 2019.
Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety
by Zacks Equity Research
Neogen's (NEOG) proprietary testing platform gets upgraded to reduce the incidence of bacterial contamination in livestock.
NuVasive's New TLIF Implant Broadens Spine Surgery Option
by Zacks Equity Research
NuVasive's (NUVA) Modulus TLIF-A is designed to work smoothly with the existing MAS TLIF and MAS Midline access systems.
EYE vs. HAE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. HAE: Which Stock Is the Better Value Option?
Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod
by Zacks Equity Research
Boston Scientific's (BSX) Vercise Gevia DBS system should boost neuromodulation revenues for the company.
Baxter (BAX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
National Vision (EYE) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
National Vision's (EYE) Military brand registers robust growth while other brands fail to impress.
National Vision (EYE) Q2 Earnings Miss Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of -4.76% and 1.99%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Q2 Earnings Preview: What's in the Cards?
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is National Vision (EYE) Down 4.7% Since Last Earnings Report?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision's (EYE) Q1 Earnings Beat, Margins Decline
by Zacks Equity Research
National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.
National Vision (EYE) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 3.13% and 1.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is National Vision (EYE) Down 7% Since Last Earnings Report?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision (EYE) Rides on Positive Comps Amid Cost Woes
by Zacks Equity Research
National Vision (EYE) has been witnessing positive comps owing to increased customer transaction over the last 68 sequential quarters.
Cooper Companies' (COO) CooperVision Gains Momentum Globally
by Zacks Equity Research
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.
National Vision (EYE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Vision (EYE) Q3 Earnings Match Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 0.00% and 2.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for Humana (HUM) Stock in Q3 Earnings?
by Zacks Equity Research
Humana's (HUM) Q3 is likely to gain from solid segmental performances and higher enrollment.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q4 Earnings?
by Zacks Equity Research
Myriad (MYGN) likely to deliver solid Q4 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
What's in Store for Penumbra (PEN) This Earnings Season?
by Zacks Equity Research
Penumbra (PEN) deepens focus on driving innovation, ramping up production and expanding geographies.
Can Dental Growth Drive Henry Schein's (HSIC) Q2 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is strongly placed to gain from the ongoing trend of digitalization in the global dental market.
4 Toxic Stocks to Discard or Sell Short for Solid Gains
by Zacks Equity Research
Overblown toxic stocks are usually vulnerable to outside shocks and loaded with a high level of debt.